Sagimet Biosciences Inc. Series A Common Stock (SGMT) — Financial Flexibility Index
Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a Financial Flexibility Index of -1.63x as of March 2026. Free cash flow of $-8.61 Million (operating CF $-8.61 Million minus capex $0.00) represents -2% of total liabilities ($5.30 Million). Also explore Sagimet Biosciences Inc. Series A Common annual equity growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Sagimet Biosciences Inc. Series A Common Stock Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Sagimet Biosciences Inc. Series A Common Stock across 7 annual periods. Check Sagimet Biosciences Inc. Series A Common strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
Year-by-year free cash flow to debt coverage for Sagimet Biosciences Inc. Series A Common Stock. For the full company profile including market capitalisation, see market value of Sagimet Biosciences Inc. Series A Common.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -8.95x | $-45.65 Million | $-45.65 Million | $5.10 Million | ▲ +6.1% |
| 2024 | -9.53x | $-42.44 Million | $-42.44 Million | $4.45 Million | ▼ -126.7% |
| 2023 | -4.20x | $-23.77 Million | $-23.77 Million | $5.65 Million | ▼ -3675.7% |
| 2022 | -0.11x | $-24.49 Million | $-24.49 Million | $219.98 Million | ▼ -11.4% |
| 2021 | -0.10x | $-21.71 Million | $-21.71 Million | $217.29 Million | ▼ -96.5% |
| 2020 | -0.05x | $-10.42 Million | $-10.42 Million | $204.87 Million | ▲ +34.2% |
| 2019 | -0.08x | $-10.55 Million | $-10.55 Million | $136.47 Million | — |